Abstract: The present invention is directed to a recombinant herpesvirus comprising a heterologous polypeptide ligand capable of binding to a target molecule and fused to or inserted into glycoprotein B at specific sites. The herpesvirus may comprise more than one ligand, and the additional ligand(s) may be comprised by a modified glycoprotein D and/or modified glycoprotein H. This allows the herpesvirus to target a cell for therapeutic purposes, and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gB, a polypeptide comprising the gB, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.

Abstract: The present invention relates to a method for making a device for monitoring the structural integrity of structures such as beams, plates and shells, made of isotropic, anisotropic and/or laminated material, and to such a device. The method provides to define a asymmetric directivity function D(k1,k2) that has, in the domain of wave numbers, a plurality of maxima arranged on different concentric circumferences having center in the origin of the axes. Then a load distribution in spatial coordinates f(x1,x2) is computed by inverse Fourier transform of the directivity function D(k1,k2). Then therefore the device is made with the electrodes, whose shape is obtained by gathering the values of the load distribution f(x1,x2) in the plane having for coordinates the set of real numbers and imaginary numbers, defining at least two sectors of said plane that comprise at least one real value and one imaginary value.

Abstract: The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines of Formula (I) that function as type II topoisomerase inhibitors and their use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4-amino-2-pyrido bicyclic pyrimidines of Formula (I).

Abstract: The present invention relates to a process of preparation of carboxylic acids by oxidative cleavage of at least one vicinal diol or an epoxide in the presence of an oxidant comprising molecular oxygen and a heterogeneous catalyst comprising a copper oxide.

Abstract: The present invention refers to a method performed in vitro to determine a Head and Neck Squamous Cell Carcinoma, preferably at early stage, based on the measuring of the hypermethylation and/or hypomethylation level(s) of CpG islands of specific set of genes.

Abstract: Supercapacitive bioelectrical systems (SC-BESs) wherein the anode and cathode act as electrodes for a self-powered internal supercapacitor. The BES may further be enhanced by the use of optimized catalysts and enzymes to increase cell voltage and the use of a third capacitive electrode (AdE) short-circuited to the BES cathode and coupled to the BES anode to improve the power output of the self-powered internal supercapacitor.

Abstract: A meter apparatus is provided for determining parameters of an AC electric signal in first and second wires, the AC signal including an AC electric current and an AC electric voltage, the apparatus including a measurement section to provide first and second measure signals each one indicative of the AC voltage based on a first capacitive coupling with the first wire and on a second capacitive coupling with the second wire, the first and second measure signals depending on capacitance values of the first and second capacitive couplings, and a control unit to determine said capacitance values of the first and second capacitive couplings according to the first and second measure signals, and determining the amplitude of the AC voltage according to the first or second measure signal, and to the capacitance values of the first and second capacitive couplings.

Abstract: Layered double hydroxides organo-modified by 3-(4-hydroxyphenyl)propionic acid (HPPA), by 2-(4-hydroxyphenyl)ethylsulfonic acid or by a hydroxyphenylpropenoic acid, and to composite polymer materials having same. The composite materials are advantageously made of biosourced polymers such as poly(butylene succinate). These composite materials have improved properties over the polymers that make up the composition thereof, and over the composites of the prior art.

Abstract: Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein.

Abstract: The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.

Abstract: The invention relates to blood serum, preferably from umbilical cord blood, for use in the treatment of neurodegenerative pathologies in the ophthalmic field, in particular in the treatment of glaucoma, wherein said serum comprises the nerve growth factor-? (NGF-?) together with other factors, such as, for example, BDNF. The serum can also be used for the treatment of ophthalmologic pathologies whose progression is linked to the activation of neuroinflammatory processes. The invention also relates to a composition comprising said serum and one or more excipients, and/or carriers and/or preservatives acceptable for human use; said composition can for example be in the form of a collyrium. Another aspect of the invention relates to a method for preparing the serum for the use, according to the invention, from blood, preferably from umbilical cord blood.

Abstract: A method is for the preparation of furoic acid or of one of its derivatives of formula (I): in which R1, R2, R3 and R4 represent, independently of each other, a hydrogen atom, a linear or branched C1-C6 alkyl group, a —C(?O)—H group or a —COOH group, by heterogeneous catalytic oxidation of furfural or a derivative thereof of formula (II). The oxidation is carried out in the presence of a supported catalyst based on gold nanoparticles, and in a non-alkaline aqueous medium. A composition useful in the method includes at least furfural and supported gold nanoparticles.

Abstract: The present invention is directed to a recombinant herpesvirus comprising a heterologous polypeptide ligand capable of binding to a target molecule and fused to or inserted into glycoprotein B at specific sites. The herpesvirus may comprise more than one ligand, and the additional ligand(s) may be comprised by a modified glycoprotein D and/or modified glycoprotein H. This allows the herpesvirus to target a cell for therapeutic purposes, and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gB, a polypeptide comprising the gB, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.

Abstract: The present invention is directed to a recombinant herpesvirus comprising a heterologous peptide and optionally polypeptide ligand capable of binding to (a) target molecule(s) and fused to or inserted into glycoprotein D. The recombinant herpesvirus may additionally comprise modifications for detargeting the virus from the natural receptors of gD. This allows the herpesvirus to efficiently target a cell for therapeutic purposes and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gD, a polypeptide comprising the gD, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.

Abstract: The present invention relates to compositions comprising a polymeric matrix or a gel containing functional enzymes capable of re-creating under culture conditions the cell microenvironment existing in vivo. The present invention also relates to devices for cell cultures comprising such compositions, in particular hydrogel and the use thereof to control the chemical microenvironment of a cell culture or mimic physiological or pathological conditions of the in vivo cells. The compositions and the devices described herein could be also used in vitro for evaluating the therapeutic effect of a compound on a determined cell line or on primary cells.

Abstract: The present invention is directed to a recombinant herpesvirus which comprises the GCN4 yeast transcription factor or a part thereof fused to or inserted into glycoprotein H and is capable of binding to a target molecule present on a cell for propagation and production of the herpesvirus. The herpesvirus may comprise additional modification in glycoprotein D and/or glycoprotein B for retargeting the herpesvirus to a diseased cell. The present invention is further directed to a nucleic acid and a vector coding for the gH, a polypeptide comprising the gH, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, the present invention is directed to a cell having accessible on the surface a target molecule for the GCN4 yeast transcription factor or part thereof and to a method for producing the herpesvirus in said cell.

Abstract: The present invention relates to the field of disease therapy. More specifically, it relates to a retargeted herpesvirus having a heterologous polypeptide fused to glycoprotein H, wherein the polypeptide targets diseased cells. It also relates to a nucleic acid comprising the genome of the herpesvirus of the invention, a vector comprising this nucleic acid and a cell comprising the nucleic acid or the vector. It further relates to killing cells using the herpesvirus of the invention and to methods for growing it in vitro.

Abstract: The present invention relates to a diagnostic/prognostic method for the identification of patients at low risk and high risk of developing colorectal cancer from a sample of human entire blood and/or blood fractions comprising nucleic acids, and to the use of a kit for performing said method.

Abstract: The present invention relates to methods of restoring brain development in individuals with Down syndrome with a flavone derivative, 7,8-dihydroxyflavone (7,8-DHF).

Abstract: A system and method for ray launching in electromagnetic wave propagation modeling. A data-processing system receives a dataset that is representative of one or more structures within an environment. The system partitions at least a first surface of a first structure into a first plurality of tiles. The system then projects a first set of ray tubes from a predetermined first point within the environment, to the tiles in the first plurality. Each ray tube in the first set is projected to a corresponding tile in the first plurality, based on whether the reference point of the corresponding tile in the first plurality is visible from the transmit point. The data-processing system evaluates the incidence of bounced ray tubes at a predetermined receive point within the environment and then presents a propagation result that is based on the evaluated incidence of the bounced ray tubes.